Skip to content
DataLookout
Start free
Menu

NCT03085056

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

See at-risk trials from Memorial Sloan Kettering Cancer Center

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 13 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Sep 2027
    • Eligibility criteria expanded, about 39 words
  2. Primary and study completion dates: Sep 2025 to Sep 2026v16
  3. Primary and study completion dates: Sep 2024 to Sep 2025v15
  4. Primary and study completion dates: Sep 2023 to Sep 2024
    • Study sites revised (7)
    v14
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 12 to confirmed 13
    • Site details revised at 7 of 7 sites
    v12
Show 7 earlier versionsHide 7 earlier versions
  1. Primary and study completion dates: Sep 2021 to Sep 2023v11
  2. Eligibility criteria shortened, about 32 words
    • Study sites: 1 to 7
    v10
  3. Primary and study completion dates: Sep 2020 to Sep 2021v9
  4. Primary and study completion dates: Sep 2019 to Sep 2020v8
  5. Primary and study completion dates: Mar 2019 to Sep 2019v7
  6. Primary and study completion dates: Mar 2018 to Mar 2019v6
  7. Phase: Not applicable to Early Phase 1v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free Survival (PFS)
Timeframe: 6 months

Arms and interventions

Trametinib in Combination With PaclitaxelExperimental

Patients will receive paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.

Drugs: Trametinib, Paclitaxel

Sites

7 sites in 1 country